Preview complete
The prescreener preview is complete. You may now close the preview.
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITYDetailed Description
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of
Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label,
randomized, controlled and will enroll up to 50 patients.
Patients in the Phase 2 cohort will be randomized 1:1 to either Hydroxychloroquine Cohort or
Comparator Cohort.
All patients in the study will follow the same visit and assessment schedule. Following
randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks
4, 12, and 24. Patients will not receive study drug during a 24-week withdrawal period
between Weeks 25 and 48. Patients will also be scheduled to be assessed at an in person
follow up visit at Week 36, and 48.
Simple Text Block
You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.
Call 1800-9860-568 now to find out if you are eligible.
Check your eligibility
Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.
Age
3 - 18
Gender
All
NCT ID
NCT04937907
Phase
2
Status
Recruiting Now
Medical Condition
Alport Syndrome
How is Plaque Psoriasis treated?
Medical Condition
A short sentence to introduce what to expect in the about condition section
Learn moreThe Study
A short sentence to introduce what to expect in the about condition section
Learn moreAbout Clinical Trials
A short sentence to introduce what to expect in the about condition section
Learn moreYour Journey
01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.